- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Imron Aly, JD: The Issues at Stake in Oil States
Speaking with the The Center for Biosimilars® the day before the Supreme Court of the United States ruled in Oil States Energy Services, LLC, v Greene’s Energy Group, LLC, Imron Aly, JD, partner at Schiff Hardin, LLP, explained the issues at stake in the case.
Transcript:
What are some of the issues at stake in the Oil States case?
So what that will end up meaning is, 1 of 3 things could happen. One, the Supreme Court could say that [inter partes reviews, IPRs] are not constitutional, and that means that no one can use that way to challenge validity of a patent. The second thing that could happen is the same thing, but only for a prospective, going forward, nature—saying that what’s happened has happened, but going forward, no one can use that system. Third—what I think most people are predicting would be likely to happen—is that the Supreme Court would say, they’re constitutional, and perhaps limited in certain ways of executing them, or requiring procedural safeguards for when and how they’re used, but that they’re likely to be constitutional. So those are some of the issues at stake.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
